Similar User
@fred_hirsch
@HosseinBorghaei
@DrRoyHerbstYale
@BenjaminBesseMD
@LudaBazhenovaMD
@CoreyLangerMD
@MattGubensMD
@geoff_oxnard
@JSabari
@RamalingamMD
@bensolomon1
@christine_lovly
@LealTiciana
@MNagasaka
@MLJohnsonMD2
Systematic review & network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as 1L treatment for advanced ALK-NSCLC. lungcancerjournal.info/article/S0169-… @ALKpositiveINT @ALKPositiveinc @LCAM_org
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activa… pubmed.ncbi.nlm.nih.gov/38938224/ Now indexed in pubmed. @LCAM_org @TheALCF @EGFRmNSCLC @EGFRResisters @EGFRSummit
The 20 papers that shaped the advancement of EGFR+ NSCLC treatment since the discovery of EGFR mutations. Commemoration of 20th anniversary of EGFR mutations discovery | LCTT @DovePress dovepress.com/top-20-egfr-ns… @DovePress @LeXiuning @ElaineShumMD @MNagasaka
20 papers/20 years/20th anniversary of EGFR mutations discovery. 21 panel members, 87 candidate papers, 59 ranked, top 30 annotated. Goal is to serve as a "syllabus" for training of future thoracic oncologists @DovePress dovepress.com/article_metric… @EGFRmNSCLC @Tony_Calles
EXCLAIM-2 presidential symposium. Chemotherapy over performed, PFS 9.6 months. HR=1.04. Still searching for EGFR TKI monotherapy in EGFRex20ins.#esmoasia2023
MARIPOSA performed better among Asians. LA arm got to 27.5 months and a HR close to FLAURA-2. Also Osi performed as well as Laz. 18.2 m vs.18.3 m. #esmo2023asia
Letter to Editor. Re “de Leeuw SP, et al. Analysis of Serious Weight G... sciencedirect.com/science/articl…. A clinical situation that is worth studying. Incretins for ALK TKI induced excessive weight gain? @ALKPositiveinc @ALKpositiveINT
Congratulations to Dr. Nagasaka for bring the manuscript to the finish line. Pan-tumor survey of RET fusions as detected by next-generation RNA seq... sciencedirect.com/science/articl… @MNagasaka @DrSteveMartin @chulkimMD @MarkSocinski
Quick editorial. Anticiapte Lorlatinib will have a long median PFS among Asians than alectinib despite the excellent PFS achieved by ALESIA. pubmed.ncbi.nlm.nih.gov/37440867/ @ALKPositiveinc @ALKpositiveINT
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation A… pubmed.ncbi.nlm.nih.gov/37377783/ @ALKPositiveinc @ALKpositiveINT
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FD… pubmed.ncbi.nlm.nih.gov/37383584/
From ASCEND-5 to ALUR to ALTA-3 | LCTT @DovePress dovepress.com/from-ascend-5-… @ALKpositiveINT @ALKPositiveinc
Additional exclusions of ROS1 fusions | LCTT @DovePress dovepress.com/the-additional…. A food for thought editorial on harmonizing ICIs ceoteria for use in EGFR/ALK/ROS1/TET+ NSCLC.
Critical Review in Oncology Hematology. Figures to argue for using Lorlatinib as 1L treatment of advanced ALK+NSCLC. Open access. @ALKpositiveINT @ALKPositiveinc PMID:37187318.
From preclinical efficacy to 2022 updated CROWN trial, lorlatinib is t... sciencedirect.com/science/articl… Finally after 6 months now the slides I used can be shared. Galley proof final version should be available soon. @MNagasaka @ALKpositiveINT @ALKPositiveinc @LCAM_org @TargetedOnc
Online today. LDCT lung cancer screening in Asian female never-smoker is as efficacious as screening or Asian male ever-smokers. Open access.@JTOonline @LCAM_org @lcsmchat @MNagasaka @ElaineShumMD
AddThis | Home doi.org/10.1016/j.jtho… @MNagasaka @ElaineShumMD @TheALCF @LCAM_org
jtocrr.org/article/S2666-…. Open Access. JTO-CRR. All you need to know about paxlovid drug-drug interaction with TKIs specific to lung cancer. @MNagasaka @TargetedOnc @LCAM_org @lcsmchat @alexchan928
Thanks @StephenVLiu 24 months preparation. Rejected once by JTO. ADAURA is positive. 71.4% never-smokers. LIBRETTO-432 will be positive. Need systemic screening of never-smokers to benefit from all these adjuvant trial. @MNagasaka @ElaineShumMD
Review and meta-analysis of low dose computed tomography (LDCT) screening for lung cancer in Asian female never-smokers @JTOonline Relative risk of lung cancer in this select population of female never smokers approaches that of male ever-smokers in Asia. jto.org/article/S1556-…
United States Trends
- 1. Serrano 134 B posts
- 2. #TysonPaul 74 B posts
- 3. #NetflixFight 38,7 B posts
- 4. #netflixcrash 4.102 posts
- 5. Ramos 63,4 B posts
- 6. #buffering 6.428 posts
- 7. ROBBED 59,9 B posts
- 8. Rosie Perez 8.002 posts
- 9. My Netflix 47,5 B posts
- 10. Jerry Jones 6.765 posts
- 11. Cedric 13,3 B posts
- 12. #boxing 35,2 B posts
- 13. Christmas Day N/A
- 14. WTF Netflix 11,2 B posts
- 15. Love is Blind 4.275 posts
- 16. The Netflix 221 B posts
- 17. $NFLX 4.440 posts
- 18. Streameast 2.384 posts
- 19. Robbery 17,7 B posts
- 20. Peter 152 B posts
Who to follow
-
Fred R. Hirsch
@fred_hirsch -
Hossein Borghaei, DO
@HosseinBorghaei -
Roy Herbst
@DrRoyHerbstYale -
Benjamin Besse
@BenjaminBesseMD -
LudaBazhenovaMD
@LudaBazhenovaMD -
Corey Langer
@CoreyLangerMD -
Matthew Gubens
@MattGubensMD -
Geoff Oxnard MD
@geoff_oxnard -
Joshua Sabari, MD
@JSabari -
Suresh S. Ramalingam, MD, FASCO
@RamalingamMD -
Ben Solomon
@bensolomon1 -
Christine Lovly, MD, PhD
@christine_lovly -
Ticiana Batista (Leal)
@LealTiciana -
Misako Nagasaka
@MNagasaka -
Melissa L. Johnson
@MLJohnsonMD2
Something went wrong.
Something went wrong.